Amgen’s MariTide Demonstrates Robust Weight Loss in Phase 2 Study for Obesity and Overweight Individuals

Amgen announced significant results from a Phase 2 study of its investigational weight loss drug, MariTide (maridebart cafraglutide), which demonstrated substantial weight loss in individuals living with obesity or overweight. The study, which enrolled 592 adults, showed that MariTide achieved up to approximately 20% average weight loss at 52 weeks without a weight loss plateau in participants without Type 2 diabetes.

In the study, participants with Type 2 diabetes and obesity or overweight also experienced notable weight loss, with up to approximately 17% average weight loss and a reduction in their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52. This is particularly significant as individuals with Type 2 diabetes typically lose less weight on GLP-1 therapies.

MariTide, a bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, is administered subcutaneously on a monthly or less frequent basis. It has shown robust and clinically meaningful improvements in cardiometabolic parameters, including blood pressure, triglycerides, and high-sensitivity C-reactive protein (hs-CRP), without significant increases in free fatty acids or changes in bone mineral density.

The ongoing Phase 2 study is now entering Part 2, where participants will be evaluated for further weight loss with continued treatment, weight maintenance through less frequent or lower dosing, and the durability of weight loss after discontinuation of MariTide. More than 90% of eligible patients chose to continue participating in Part 2 of the study.

Amgen is initiating “MARITIME,” a Phase 3 clinical development program for MariTide, targeting obesity and related conditions. This move reflects the company’s confidence in MariTide’s potential as a unique treatment option for patients with obesity and overweight.